Retatrutide Deep Dive

Version 1 · Sep 8, 2026

What retatrutide is, what the trials actually show, and where the evidence stops

What retatrutide is

Retatrutide is an investigational Eli Lilly compound that activates three receptors at once: GLP-1, GIP, and glucagon. Semaglutide targets one of those. Tirzepatide targets two. The third receptor, glucagon, is what separates it: rather than only reducing how much you eat, it also raises how much energy you burn and mobilises stored fat directly.

It is not approved. It is in Phase 3 trials, with an FDA decision not expected before 2027. Everything written here is educational, describes trial data, and is not medical advice or a dosing recommendation.

How it compares

In the Phase 2 trial published in the New England Journal of Medicine in 2023 (DOI 10.1056/NEJMoa2301972, n=338), the 12 mg dose produced roughly 24% body-weight reduction at 48 weeks. Longer Phase 3 follow-up puts the figure near 28% at 80 weeks. For context, tirzepatide's best published result is around 21%, and 30% is the threshold historically associated with bariatric surgery.

The dose-response curve flattens sharply. Moving from 1 mg to 4 mg adds about 8 percentage points of weight loss; 4 mg to 8 mg adds under 6; 8 mg to 12 mg adds barely 1. Most of the available benefit arrives well below the top dose, with fewer gastrointestinal side effects.

FindingEvidenceSource
Retatrutide Dose-Response Is Sigmoidal, Not Linear
The dose-response curve for retatrutide follows a sigmoidal pattern. The difference between 4mg and 8mg was only a 5% increase in fat loss but a 300% increase in side effects. 5mg in a properly nourished individual produ		RCTsource
Retatrutide Produced 24% Body Weight Loss in Clinical Trial
The Jastasterb study (2023, New England Journal of Medicine) showed retatrutide produced approximately 24% body weight reduction over 48 weeks in obese subjects, with 90% of the weight lost being fat. Described as the mo		RCTsource
Retatrutide Dose-Response Analysis: 4-6 mg/week Range Assessment
Phase 2 trial (NEJM 2023, n=338) tested 1/4/8/12 mg arms. 4 mg achieved -17.1% mean weight loss at 48 weeks (92% lost >=5%, 75% >=10%, 60% >=15%). 8 mg achieved -22.8%, 12 mg -24.2%. Dose-response shows diminishing retur		RCTsource
Retatrutide Phase 2 Trial: Continuous Weight Loss Through Week 48
The phase 2 clinical trial of retatrutide demonstrated that weight loss did not plateau at week 12 but continued through week 48 at the highest dose. Most trial participants were still titrating up at week 12 and had not		RCTsource
Retatrutide 12mg Produces ~28% Weight Loss at 80 Weeks in Phase 3 Trial
In the Triumph 1 Phase 3 randomized double-blind placebo-controlled trial (n>2,300 adults with obesity/overweight, no diabetes), retatrutide 12mg produced an average weight loss of 28.3% (70.3 lbs) from a baseline of ~24		RCTsource
Retatrutide 9mg Produces ~26% Weight Loss at 80 Weeks
In the Triumph 1 Phase 3 trial, retatrutide 9mg produced an average weight loss of 25.9% (64.4 lbs) at 80 weeks based on the efficacy estimate. The treatment regimen estimate yielded 23.7% weight loss. Participants start		RCTsource
Retatrutide 4mg Produces ~19% Weight Loss at 80 Weeks with Single Dose Escalation
In the Triumph 1 Phase 3 trial, retatrutide 4mg produced an average weight loss of 19% (47.2 lbs) at 80 weeks (efficacy estimate), with a treatment regimen estimate of 17.6%. Notably, the 4mg group required only one dose		RCTsource
Retatrutide Dose Escalation Protocol: Gradual Weekly Titration Starting at 2mg
All participants in the Triumph 1 trial started retatrutide at 2mg once weekly and escalated every 4 weeks until reaching their assigned target dose. The 12mg group stepped through 2mg, 4mg, 6mg, 9mg, and then 12mg. This		RCTsource

What it does to muscle

This is where popular summaries get it wrong, so it is worth stating precisely. Retatrutide is clearly better than semaglutide for preserving lean mass: roughly 75 to 80% of the weight lost is fat, against about 60% for semaglutide.

Against tirzepatide, however, the two are comparable. The first DEXA body-composition data showed the same rough 75 to 80% fat-to-lean ratio for both drugs. The specific hypothesis that glucagon-receptor activation would preferentially spare muscle was tested and refuted.

There is a practical consequence that cuts the other way. Because retatrutide produces greater total weight loss at the same ratio, the absolute number of pounds of lean mass lost can be higher. Adequate protein intake and resistance training matter more on this compound, not less.

FindingEvidenceSource
Retatrutide Body Composition: Fat vs. Lean Mass Loss Ratio from First DEXA Data
The Lancet published the first DEXA scan body composition data on retatrutide in 103 people with type 2 diabetes over 36 weeks. At the 12 mg dose, approximately 75–80% of total weight lost was fat mass, with the remainin		RCTsource
Retatrutide 12 mg Dose: Total Fat Mass Reduction of 23%
At the 12 mg dose of retatrutide, total fat mass dropped by 23% over 36 weeks as measured by DEXA scan in a Lancet-published study of 103 type 2 diabetes patients. This represents a clinically significant reduction in ov		RCTsource
Retatrutide 12 mg Dose: Visceral Fat Reduction of 31%
Retatrutide at 12 mg produced a 31% reduction in visceral fat — the metabolically dangerous fat surrounding internal organs — over 36 weeks per DEXA scan data. This exceeds the overall fat mass reduction of 23%, suggesti		RCTsource
Retatrutide Absolute Lean Mass Loss: 10–15 lbs at 12 mg Dose
Despite a favorable fat-to-lean loss ratio of 75–80% fat, the large absolute weight loss on retatrutide (approximately 50 lbs at 12 mg) means users may lose 10–15 lbs of lean mass. The speaker emphasizes that the absolut		RCTsource
Retatrutide vs. Tirzepatide: Comparable Fat-to-Lean Mass Loss Ratio (~75% Fat)
DEXA data shows retatrutide and tirzepatide have comparable body composition profiles during weight loss, with both losing approximately 75% fat and 25% lean mass. This comparison positions retatrutide as similar to tirz		RCTsource
Semaglutide Inferior Fat-to-Lean Mass Ratio Compared to Retatrutide and Tirzepatide
Semaglutide demonstrates a less favorable body composition profile during weight loss compared to retatrutide and tirzepatide, losing approximately 60% fat and 40% lean mass. This suggests that GLP-1 mono-agonism without		RCTsource
Glucagon Receptor Agonism Does NOT Preferentially Spare Muscle vs. Fat — Hypothesis Refuted
A prevailing hypothesis held that retatrutide's glucagon receptor component would shift energy expenditure toward fat oxidation and preferentially spare lean mass. The DEXA scan data refutes this, showing retatrutide's f		RCTsource
Retatrutide Phase 2 Trial: Only ~74% of Weight Lost Was Fat Mass
In the Phase 2 clinical trial of retatrutide, approximately 74% of total weight lost was attributable to fat mass, meaning roughly 26% came from non-fat sources including lean/muscle tissue and potentially organ size red		RCTsource

Effects beyond weight loss

The trial data extends past the scale. Retatrutide monotherapy reduced liver fat by roughly half in patients with fatty liver disease, with meaningful improvement in fibrosis markers. Insulin sensitivity improved substantially, and adiponectin, an anti-inflammatory signal produced by fat tissue, rose sharply while inflammatory cytokines fell.

That last mechanism is notable because it appears to operate independently of weight loss: the drug changes what fat tissue does, not merely how much of it there is.

FindingEvidenceSource
Tesamorelin Added at Week 3-4 for Muscle Preservation
Tesamorelin (a GH-releasing hormone analog) should be added at week 3-4 of retatrutide therapy for muscle preservation, not just visceral fat loss. It increases growth hormone secretion in a pulsatile pattern, activating		RCTsource
Retatrutide Reduces Fasting Insulin by 55% and HOMA-IR by 60%
A 2023 JAMA study showed Retatrutide monotherapy reduced fasting insulin by 55% and improved HOMA-IR (insulin resistance index) by 60% in non-diabetic individuals with metabolic dysfunction. The speaker emphasizes this w		RCTsource
Retatrutide Monotherapy Reduces Liver Fat by 54% and Improves Fibrosis Markers by 70% in NAFLD
A 2023 study in Gastroenterology showed Retatrutide monotherapy reduced liver fat content by 54% in NAFLD patients and improved fibrosis markers by over 70%. The mechanism involves reducing free fatty acid delivery to th		RCTsource
Retatrutide Increased Adiponectin Production by 340%
A 2023 study in Molecular Metabolism showed Retatrutide specifically increased adiponectin production by 340%. Fat cells change their gene expression under Retatrutide, producing less inflammatory cytokines (TNF-alpha, I		RCTsource
Retatrutide Improved HOMA-IR by 68% Over 6 Months
A 2023 New England Journal of Medicine study showed Retatrutide improved HOMA-IR (insulin resistance measure) by 68% over 6 months, working by reducing nutrient overload, improving hepatic insulin clearance, and restorin		RCTsource
Retatrutide 12 mg Dose: Visceral Fat Reduction of 31%
Retatrutide at 12 mg produced a 31% reduction in visceral fat — the metabolically dangerous fat surrounding internal organs — over 36 weeks per DEXA scan data. This exceeds the overall fat mass reduction of 23%, suggesti		RCTsource
Retatrutide Liver Fat Reduction: Dose-Dependent Jump at 4mg Indicating Glucagon Activity
Retatrutide demonstrates dose-dependent liver fat reduction, with a notable jump between 1mg and 4mg doses. At 1mg, liver fat decreased by 43%, while at 4mg it decreased by 57% — a 14 percentage point increase. The speak		RCTsource
Retatrutide Glucagon Receptor Activation Confirmed by Three Convergent Biomarkers at 4mg
The speaker presents three convergent lines of clinical trial evidence that the glucagon receptor becomes meaningfully activated at the 4mg retatrutide dose: (1) dysesthesia incidence jumps from near-zero at 1mg to 8% at		RCTsource

Dosing and diminishing returns

Trial doses ranged from 1 mg to 12 mg weekly. The practical observation from the dose-response data is that side effects scale faster than benefit above roughly 4 to 6 mg per week. This is trial information, not a protocol: the compound is unapproved and dosing decisions belong with a physician.

FindingEvidenceSource
Retatrutide Dose-Response Is Sigmoidal, Not Linear
The dose-response curve for retatrutide follows a sigmoidal pattern. The difference between 4mg and 8mg was only a 5% increase in fat loss but a 300% increase in side effects. 5mg in a properly nourished individual produ		RCTsource
Retatrutide Dose-Response Analysis: 4-6 mg/week Range Assessment
Phase 2 trial (NEJM 2023, n=338) tested 1/4/8/12 mg arms. 4 mg achieved -17.1% mean weight loss at 48 weeks (92% lost >=5%, 75% >=10%, 60% >=15%). 8 mg achieved -22.8%, 12 mg -24.2%. Dose-response shows diminishing retur		RCTsource
Low-Dose vs. High-Dose Retatrutide: Comparable Efficacy with Fewer GI Side Effects at Lower Doses
The 2023 New England Journal of Medicine phase 2 retatrutide trial compared lower starting doses against more aggressive starting doses and found comparable weight loss results at week 48 with significantly fewer GI side		RCTsource
Retatrutide 4mg Produces ~19% Weight Loss at 80 Weeks with Single Dose Escalation
In the Triumph 1 Phase 3 trial, retatrutide 4mg produced an average weight loss of 19% (47.2 lbs) at 80 weeks (efficacy estimate), with a treatment regimen estimate of 17.6%. Notably, the 4mg group required only one dose		RCTsource
Retatrutide Dose Escalation Protocol: Gradual Weekly Titration Starting at 2mg
All participants in the Triumph 1 trial started retatrutide at 2mg once weekly and escalated every 4 weeks until reaching their assigned target dose. The 12mg group stepped through 2mg, 4mg, 6mg, 9mg, and then 12mg. This		RCTsource
Retatrutide Discontinuation Rates Due to Adverse Events Are Dose-Dependent
Discontinuation rates due to adverse events in Triumph 1 were dose-dependent: 4.1% at 4mg, 6.9% at 9mg, and 11.3% at 12mg, compared to 4.9% with placebo. The 11.3% rate at the highest dose is considered meaningful but no		RCTsource
Retatrutide Dose Titration Protocol in Triumph 1
All participants on retatrutide began at 2 mg once weekly and escalated every 4 weeks until reaching their assigned target dose. The 12 mg group stepped through 2, 4, 6, 9, and then 12 mg sequentially. The 4 mg group req		RCTsource
Retatrutide GI Adverse Events at 12 mg Dose
At the 12 mg dose in Triumph 1, nausea occurred in 42.4% of participants, diarrhea in 32%, constipation in 26.1%, and vomiting in 25.3% — all clearly elevated compared to placebo. These are consistent with the known clas		RCTsource

Safety and open questions

The clearest dose-dependent signal in the Phase 3 data is dysesthesia, abnormal skin sensations such as burning or tingling, reported by around 12% of participants at the higher doses against under 1% on placebo. Heart rate rises and peaks around week 24, also dose-dependently.

Two further caveats matter. Stopping abruptly is likely to produce substantial regain, based on discontinuation data from the same drug class. And durability is unknown: surgical comparisons draw on ten to twenty years of follow-up, while retatrutide data extends to roughly two.

FindingEvidenceSource
Retatrutide Heart Rate Elevation Peaks at Week 24 Due to Glucagon Receptor Activation
In the phase 2 retatrutide trial, heart rate elevation did not peak in the early weeks but instead peaked around week 24, and was dose-dependent — higher doses produced greater heart rate elevation at peak. This is attri		RCTsource
Retatrutide Safety Warning: Distinguishing Adaptation Side Effects from Serious Adverse Events
Mild nausea, soft stools, and appetite suppression in weeks 1–4 are considered normal adaptation responses and do not require stopping. However, severe vomiting, jaundice (yellowing of skin/eyes), sustained tachycardia, 		expert-opinionsource
Caution Against Low-Dose Retatrutide for Already-Healthy Individuals
The speaker expresses a cautionary stance toward using low-dose Retatrutide as a general health optimization tool in individuals who are already healthy. The core argument is that most observed health benefits from Retat		expert-opinionsource
Retatrutide GI Adverse Events at 12 mg Dose
At the 12 mg dose in Triumph 1, nausea occurred in 42.4% of participants, diarrhea in 32%, constipation in 26.1%, and vomiting in 25.3% — all clearly elevated compared to placebo. These are consistent with the known clas		RCTsource
Retatrutide Discontinuation Rates Due to Adverse Events by Dose
Discontinuation rates due to adverse events in Triumph 1 were 4.1% for retatrutide 4 mg, 6.9% for 9 mg, and 11.3% for 12 mg, compared to 4.9% for placebo. The 11.3% rate at the highest dose is meaningful but lower than f		RCTsource
Limitations of Topline Data and Need for Full Peer-Reviewed Publication
The speaker cautions that topline results are company press release previews, not full peer-reviewed publications, and that discontinuation rates alone do not capture the full tolerability picture. Missing data includes 		expert-opinionsource
Retatrutide Safety Data Limitations: Topline Results Do Not Capture Full Tolerability Picture
The speaker flags that discontinuation rates alone do not fully capture the tolerability burden of retatrutide. Missing from topline data are symptom severity, quality of life impacts, dose interruptions, dose reductions		expert-opinionsource
GLP-1 Receptor Agonists Linked to Hair Loss and Energy Decline via Malnutrition Mechanism
The speaker extends the malnutrition-driven resource-reallocation mechanism to explain additional side effects observed in GLP-1 users, specifically hair loss and plummeting energy levels. These are framed as downstream 		expert-opinionsource
Contraindication: History of Medullary Thyroid Carcinoma
The speaker explicitly states that anyone with a personal history of medullary thyroid carcinoma should not take retatrutide. This is a known class-wide contraindication shared with other GLP-1 receptor agonists.		expert-opinionsource
Contraindication: Known Hypersensitivity to Similar Drug Classes
Individuals with a known hypersensitivity to drugs similar to retatrutide (i.e., GLP-1/GIP/glucagon receptor agonists) are contraindicated from using it. The speaker does not specify which drugs or reactions qualify.		expert-opinionsource

References

  1. RETATRUTIDE Just Hit Bariatric Surgery-Level Weight Loss? — Peptide Buddy (May 2026) 50 findings
  2. Retatrutide and Cardarine Combined? - Dr Trevor Bachmeyer — Dr Trevor Bachmeyer (Mar 2026) 21 findings
  3. Retatrutide and 5-Amino-1-MQ Combined - Dr Trevor Bachmeyer — Dr Trevor Bachmeyer (Feb 2026) 17 findings
  4. STOP Combining Retatrutide and Tirzepatide - Dr Trevor Bachmeyer — Dr Trevor Bachmeyer (Mar 2026) 17 findings
  5. Retatrutide, Pregnancy and Breastfeeding - Dr Trevor Bachmeyer — Dr Trevor Bachmeyer (Mar 2026) 16 findings
  6. The Retatrutide Crackdown Just Escalated — (Here's What Changed) — PEPtalks with Mike (Aug 2026) 14 findings
  7. Stop Wasting Retatrutide! Heres the Sweet Spot (Weightloss Dr. Explains) — Dr. Kevin Joseph (Jul 2026) 14 findings
  8. Oral GLP-1 Absorption: Why Pill vs Shot Matters #shorts — Dr. Greg Jones (Aug 2026) 13 findings
  9. The Benefits & Risks of Retatrutide WATCH BEFORE TAKING — Dr. Jones, DC (Aug 2026) 12 findings
  10. Doctor Explains Why More Retatrutide Doesn't Mean Better Results - Dr Trevor Bachmeyer — Dr Trevor Bachmeyer (Mar 2026) 10 findings
  11. Peptide Therapy Not Working? Genetics Might be the Key! #shorts — Dr. Greg Jones (Sep 2026) 8 findings
  12. This New Weight-Loss Drug Works Two Ways At Once — Dr. Greg Jones (Aug 2026) 7 findings
  13. These Common Breakfast Foods are RUINING Your GLP-1 Results — Dr. Jones, DC (Aug 2026) 7 findings
  14. What Reta Actually Does To Your Muscle (First DXA Data) — Josh Holyfield (May 2026) 7 findings
  15. Can You Defeat Ozempic? Shane Gillis & Mark Normand on JRE — Peptide Buddy (May 2026) 7 findings
  16. Does MOTS-C Make You Tired? Here's the solution - Dr Trevor Bachmeyer — Dr Trevor Bachmeyer (Mar 2026) 7 findings
  17. Microdosing GLP-1s Isn't For Everyone — Stop the FOMO (Dr. Explains) — Dr. Kevin Joseph (Aug 2026) 6 findings
  18. How to Keep Your Muscle While Losing Weight on Retatrutide — Josh Holyfield (Aug 2026) 6 findings
  19. Why Food Noise Returns on GLP-1 Medications (Explained) — Josh Holyfield (Jul 2026) 6 findings
  20. What Actually Breaks Your Fast on Peptides — Josh Holyfield (May 2026) 6 findings
  21. The Revolutionary Case for NATURAL GLP-1s | Fat Loss Without Muscle Loss I Sarah Kennedy Ep #477 — Nathalie Niddam (Sep 2026) 5 findings
  22. Your Body Already Makes the Molecule That Fixes Insulin Resistance (most people block it) — Thomas DeLauer (Aug 2026) 5 findings
  23. What is the CJC-1295 Peptide? — Dr. Rob Swanda (Aug 2026) 5 findings
  24. Doctor Explains NEW Retatrutide Benefits & Findings (not what you think) — Dr. Jones, DC (Aug 2026) 5 findings
  25. This Powder is 2X Stronger than Creatine for Performance (and cheaper) — Thomas DeLauer (Jul 2026) 5 findings
  26. Investigation Muscle Protection Antibody: Bimagrumab — Dr. Rob Swanda (Aug 2026) 4 findings
  27. Retatrutide and Muscle Loss: How to Keep Your Gains on Reta — Josh Holyfield (Aug 2026) 4 findings
  28. Avoid These Retatrutide Mistakes to MAXIMIZE Weight Loss (Beginner’s Guide) — Dr. Jones, DC (May 2026) 4 findings
  29. Why You Gained the Weight Back After Stopping Your GLP-1 — Josh Holyfield (Apr 2026) 4 findings
  30. Peptides Are Insane — Jeff Nippard 3 findings
  31. I Lost 150+ Pounds — These Are the Peptides That Actually WORKED (Dr. Explains) — Dr. Kevin Joseph (Oct 2026) 3 findings
  32. Doctor Explains Why Tirzepatide is the KING of Fat Loss Peptides — Dr. Jones, DC (Sep 2026) 3 findings
  33. PT-141 Nausea Explained: The Brain's Pathway #shorts — Dr. Greg Jones (Aug 2026) 3 findings
  34. Semaglutide vs. Tirzepatide vs. Retatrutide — Dr. Rob Swanda (Jul 2026) 3 findings
  35. How Heavy Resistance Training Produces the Same Effect as a Sauna — Ben Greenfield Life (Jul 2026) 3 findings
  36. The 90-Day Protocol That Reverses Insulin Resistance | Labs & Supplements - Dr Trevor Bachmeyer — Dr Trevor Bachmeyer (Jul 2026) 3 findings
  37. This New Weight Loss Shot Isn't a GLP-1 (20% in 48 Weeks) #metabolichealth #glp1 — Dr. Jones, DC (Jul 2026) 3 findings
  38. Retatrutide Under 4mg: Are You Still Getting Glucagon Benefits? — Josh Holyfield (May 2026) 3 findings
  39. Why You Don't Need to Cycle CJC-1295 or Tesamorelin — Josh Holyfield (May 2026) 3 findings
  40. Retatrutide Hits 30% Weight Loss in Phase 3 #glp1 #weightloss — Dr. Jones, DC (Sep 2026) 2 findings
  41. 27 Peptide Vials Tested #healthoptimization #peptidetherapy — Dr. Jones, DC (Aug 2026) 2 findings
  42. The Retatrutide Crackdown: What You Need To Know — Peptide Buddy (Aug 2026) 2 findings
  43. 3 Reasons MOTS-C Makes You Worse #healthoptimization #longevity — Dr. Jones, DC (Aug 2026) 2 findings
  44. MOTS-C Boosts Fat Burning & Insulin #longevity #metabolicflexibility — Dr. Jones, DC (Aug 2026) 2 findings
  45. The Medical Industry Is Corrupt: Proof in Numbers - Dr Trevor Bachmeyer — Dr Trevor Bachmeyer (Aug 2026) 2 findings
  46. Does Retatrutide Overwork Your Pancreas? The Insulin Truth — Josh Holyfield (Aug 2026) 2 findings
  47. Doctor Explains How Retatrutide Helps Fix Autoimmune Diseases — Dr. Jones, DC (Jul 2026) 2 findings
  48. Insulin Resistance Doctor: Stop 16:8 Fasting Now (Do This Fasting Instead) — Thomas DeLauer (Jul 2026) 2 findings
  49. MOTS-C Explained: Why Exercise Activates the Same Pathway — Josh Holyfield (Jun 2026) 2 findings
  50. How to STOP Muscle Loss While Using GLP-1 Peptides — Dr. Greg Jones (Jun 2026) 2 findings
  51. AOD-9604 Doesn't Work – Do This Instead — Josh Holyfield (Jun 2026) 2 findings
  52. Retatrutide Changes Everything #glp1 #weightloss — Dr. Jones, DC (Jun 2026) 2 findings
  53. Why Growth Hormone Peptides Cause Water Retention (And How to Fix It) — Josh Holyfield (May 2026) 2 findings
  54. Stop Taking Semaglutide and Tirzepatide — Josh Holyfield (May 2026) 2 findings
  55. What Actually Causes Retatrutide Hunger (Not Glucagon) #retatrutide #glp1weightloss — Dr. Jones, DC (May 2026) 2 findings
  56. Doctor Explains How To Fix Fatty Liver Disease Fast (not what you think) — Dr. Jones, DC (May 2026) 2 findings
  57. Why Your CJC+Ipamorelin Isn't Working on Retatrutide — Josh Holyfield (Apr 2026) 2 findings
  58. Why Growth Hormone Peptides Are a Waste of Money Without Optimized Testosterone — Josh Holyfield (Apr 2026) 2 findings
  59. TRT Clinic Revenue Loop — Josh Holyfield (Mar 2026) 2 findings
  60. The 4-Step Diagnostic Every Woman Needs Before Starting Any Protocol — Josh Holyfield (Apr 2026) 2 findings
  61. Tesamorelin, CJC and Ipamorelin and CANCER - Dr Trevor Bachmeyer — Dr Trevor Bachmeyer (Mar 2026) 2 findings
  62. Do These New Peptide Replacements Make Steroids OBSOLETE? (Doctor Explains) — Dr. Jones, DC (Sep 2026) 1 finding
  63. DO THIS To DOUBLE Your Tirzepatide Results to MAXIMIZE Weight Loss — Dr. Jones, DC (Sep 2026) 1 finding
  64. You're WASTING Retatrutide! Here's the Dosing Sweet Spot (Weight Loss Doctor Explains) — Dr. Jones, DC (Sep 2026) 1 finding
  65. The New Drug You Can't Get Yet #metabolichealth #functionalmedicine — Dr. Jones, DC (Sep 2026) 1 finding
  66. Doctor Explains Biggest Peptide Side Effects (And How to Prevent Them) — Dr. Jones, DC (Sep 2026) 1 finding
  67. Doctor Explains the BEST Ozempic Substitute (not what you think) — Dr. Jones, DC (Sep 2026) 1 finding
  68. Retatrutide Kills Your Desire? The Side Effect Lilly and FDA Never Tested For — PEPtalks with Mike (Sep 2026) 1 finding
  69. Peter Attia Is Wrong About Peptides. Here’s Why — Dr. Alex Tatem (Sep 2026) 1 finding
  70. How does the Peptide Ipamorelin Work? — Dr. Rob Swanda (Aug 2026) 1 finding
  71. Why Most GLP-1s Are Injected, but This One Isn’t #shorts — Dr. Greg Jones (Aug 2026) 1 finding
  72. Why Peptide Channels Keep Getting Deleted - Dylan Gemelli x Ben Greenfield — Ben Greenfield Life (Aug 2026) 1 finding
  73. `COAs Don't Prove Your Peptides Are What You Think` — Josh Holyfield (Aug 2026) 1 finding
  74. Why Your Peptide COA Might Not Mean What You Think — Josh Holyfield (Jul 2026) 1 finding
  75. Foods That DESTROY Your Peptide Results in 2026 — Dr. Jones, DC (Jul 2026) 1 finding
  76. AOD-9604 vs HGH for Fat Loss: The Truth Nobody Tells You — Josh Holyfield (Jul 2026) 1 finding
  77. The Barbie Drug — The Truth About Melanotan II — Skinfluence with Dr. Dustin Portela (May 2026) 1 finding
  78. What Tesamorelin Actually Does #healthoptimization #hormonehealth — Dr. Jones, DC (Jun 2026) 1 finding
  79. The Peptide That Mimics Exercise Without Moving — Dr. Greg Jones (Jun 2026) 1 finding
  80. Does Tesamorelin Actually Target Visceral Fat? — Josh Holyfield (Jun 2026) 1 finding
  81. Retatrutide: Who Should (and Shouldn't) Take It — Josh Holyfield (Jun 2026) 1 finding
  82. AOD 9604: Why This Peptide Is a Waste of Money — Josh Holyfield (Jun 2026) 1 finding
  83. Your GLP-1 Is Doing More to Your Brain Than You Think — Josh Holyfield (May 2026) 1 finding
  84. Should You Take Low Dose Retatrutide for Long-Term Health? — Josh Holyfield (May 2026) 1 finding
  85. Doctor Explains GLP 1 Blindness Risk (Should You Be Worried?) — Dr. Jones, DC (May 2026) 1 finding
  86. Retatrutide Dose-Response Analysis: 4-6 mg/week Range Assessment — Unknown 1 finding
  87. Tesamorelin vs CJC-1295: The Visceral Fat Myth Explained — Josh Holyfield (May 2026) 1 finding
  88. CJC 1295 with DAC vs Without DAC and Which One You Should Actually Use — Josh Holyfield (May 2026) 1 finding
  89. CJC-1295 Buyer's Guide: 4 Decisions Before You Buy — Josh Holyfield (Apr 2026) 1 finding
  90. The Right Way to Use AOD-9604 for Weight Loss #aod9604 #peptides — Dr. Jones, DC (Apr 2026) 1 finding
  91. The BEST GLP-1 Injection Site (Science vs Reality) #glp1 #glp1weightloss — Dr. Jones, DC (Apr 2026) 1 finding
  92. The GLP-1 Weight Loss Cheat Sheet 📝 #glp1 #glp1weightloss — Dr. Jones, DC (Mar 2026) 1 finding
  93. How Much Muscle LOSS From Ozempic? 🤔 #glp1 #glp1weightloss — Dr. Jones, DC (Mar 2026) 1 finding
  94. Peptide Injection Lumps and Nodules: Why They Happen and How to Fix Them — Josh Holyfield (Mar 2026) 1 finding
  95. Doctor Explains When to Change Your GLP 1 Dose (not what you think) — Dr. Jones, DC (Apr 2026) 1 finding
  96. TB-500 Afib, Cardiac Fibrosis and Arrhythmia - Dr Trevor Bachmeyer — Dr Trevor Bachmeyer (Mar 2026) 1 finding
  97. KPV and TB500N vs Cholesterol, AFib and Heart Disease - Dr Trevor Bachmeyer — Dr Trevor Bachmeyer (Mar 2026) 1 finding
  98. Why Cold Sores Keep Coming Back (and preventing it) - Dr Trevor Bachmeyer — Dr Trevor Bachmeyer (Apr 2026) 1 finding

Evidence Tier Key